What You Should Know
- Signant Health has acquired Ametris (formerly known as ActiGraph) to combine electronic clinical outcome assessment (eCOA) technology with wearable-based digital measurements. Financial details of the acquisition were not disclosed.
- The deal addresses a primary industry bottleneck by replacing multiple disconnected vendors with a single platform for both subjective patient feedback and objective sensor data.
- The integrated system is designed to support decentralized and hybrid trial models, allowing participants to contribute data remotely from real-world environments.
- Jeremy Wyatt, CEO of Ametris, noted that the combination will accelerate the development of integrated evidence systems while simplifying vendor management for pharmaceutical sponsors.
- Signant Health serves over 600 sponsors and contract research organizations (CROs), including all of the top 20 pharmaceutical companies.
Pharmaceutical companies are increasingly seeking more comprehensive evidence to satisfy the rigorous demands of regulatory submissions and reimbursement discussions. Signant Health is moving to meet this need by acquiring Ametris, a company with two decades of experience in regulatory-aligned wearable measurement systems. This acquisition reflects a broader shift toward continuous data collection, where the combination of patient-reported symptoms and objective physiological indicators creates a richer longitudinal dataset.
Roger Smith, CEO of Signant Health, stated that the acquisition represents a commitment to advancing the possibilities of clinical evidence generation by creating a unified workflow for sponsors.
Bridging the “Subjective-Objective” Data Gap
Traditionally, clinical trials have operated in silos, with patient-reported outcomes (subjective) and sensor-based data (objective) managed through separate technologies.
- eCOA Integration: Signant’s technology captures patient feedback on symptoms, quality of life, and daily functioning.
- Wearable Precision: Ametris specializes in digital outcome measures that track physical activity and physiological markers outside of traditional clinical settings.
- Therapeutic Relevance: This multimodal approach is particularly critical for Central Nervous System (CNS) and other complex therapeutic areas where regulators require diverse forms of evidence to validate benefits.
Future-Proofing with AI and Machine Learning
Near-term plans for the merger involve unified workflows and integrated analytics, but the long-term vision focuses on the Medical Intelligence Layer. The companies plan to explore AI and machine learning applications capable of identifying hidden patterns across patient-reported and sensor-derived datasets.
This evolution could eventually lead to the development of composite outcome measures and real-time trial monitoring—capabilities that are receiving significant attention from both drug developers and global regulators.
